XJN010

XJN010 is a **chemical drug** under development as an intranasal (nasal spray) formulation for the treatment of Parkinson's disease, especially targeting patients experiencing "off" episodes. It is being developed by Guangzhou Novaken Pharmaceutical and is being studied in randomized, double-blind, placebo-controlled clinical trials. The primary goals are to assess safety, pharmacokinetics, pharmacodynamics, and efficacy in Parkinson's disease patients[1][5][9]. The exact molecular mechanism of action or specific target has not been publicly disclosed in the available clinical trial documentation and registry information as of September 2025.